The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.

The invention provides methods for the identification of patients capable of controlling HIV progression, as well as to the identification of an antagonist form of IP-10 associated to HIV progression control and the uses thereof for improving the immunological response of HIV patients.

The invention relates to in vitro method for quantitating the antibodies specific for High mobility group box I (HMGB1) contained in a sample, in particular a serum sample or a cerebrospinal fluid sample obtained from a patient, and the use of this method in the prognostic and/or diagnosis of neurological disorders. These methods are in particular applicable to the monitoring of the human immunodeficiency virus (HIV) infection of a subject who is known to be infected with HIV and in the prognostic and/or diagnostic of the state of progression of Acquired immune deficiency syndrome (AIDS) or the state of progression toward AIDS, in particular the state of progression or the state of progression toward neurological disorders associated with AIDS. Finally, the invention is also about method to determine the immune deficiency or level of immune activation of a patient, in particular a HIV-infected patient.

A four-biomarker panel for diagnosis of chronic graft-versus-host disease (cGVHD) and methods of prognosing and/or diagnosing cGVHD using the biomarker panel are disclosed.

Provided herein are methods of monitoring progression, regression, or stage of an AID in a subject, measuring a level of expression of a gene, an RNA, or a protein, or a combination thereof, in a sample obtained from a niche at the implantation site of a synthetic scaffold in the subject at a first time point and at a second time point, wherein the expression level measured at the first time point is compared to the expression level measured at the second time point, wherein the difference in the level of expression at the second time point relative to the level of expression at the first time point is indicative of progression, regression, or stage of the autoimmune disease. Related methods of detecting an AID, determining treatment for a subject with an AID, determining efficacy of an AID treatment, or treating an AID, are further provided.

Provided herein are methods, kits and reagents for analyzing attributes of engineered immune cells, such as CAR T cells. For example, provided herein are methods of determining the amount or percentage of residual TCRαβ+ CAR T cells in allogeneic CAR T cell drug product and characterizing other important attributes of CAR T cell drug product.

The present invention provides a novel method of obtaining data for predicting the onset of an adverse event due to administration of at least one antibody drug selected from an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-CTLA4 antibody, and an antigen-binding fragment thereof, or a novel method of predicting the onset of the adverse event. More specifically, the present invention provides a method of obtaining data for predicting the onset of an adverse event or a method of predicting the onset of the adverse event, comprising measuring a level of at least one marker selected from sCD163 and CXCL5 in a biological sample collected from a subject administered the antibody drug.

Provided herein am compositions and methods for characterizing and treating neurodegenerative disease. In particular, provided herein are compositions and methods for measuring T cell markers associated with Alzheimer's disease.

The invention provides methods of identifying, diagnosing, treating, and monitoring or prognosing progression of type I IFN-mediated disease or disorder in subjects. The present invention further relates to methods of identifying candidate therapeutic agents for treating a type I interferon-mediated disease or disorder.

Disclosed herein are a method and a biomarker for predicting efficacy and prognosis of or resistance to an immunotherapy. The use of the biomarkers (TCTP, EGFR, AKT, MCL1, and/or CXCL10) of the present disclosure allows the prediction of resistance to or prognosis of a cancer immunotherapeutic agent and the selection of a therapy guaranteeing therapeutic benefit, thereby finding advantageous applications in treating cancers or tumors resistant to cancer immunotherapeutic agents.